Response to Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myelogenous Leukemia Relapsing in Chronic and Advanced Phase Following Allogeneic Hematopoietic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 5, 2010, Pages 639-646

  Wright, Matthew P ^a   Shepherd, John D ^a   Barnett, Michael J ^a   Nantel, Stephen H ^a   Sutherland, Heather J ^a   Toze, Cynthia L ^a   Hogge, Donna E ^a   Nevill, Thomas J ^a   Song, Kevin W ^a   Abou Mourad, Yasser R ^a   Narayanan, Sujaatha ^a   Power, Maryse M ^a   Smith, Clayton A ^a   Forrest, Donna L ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Allogeneic transplantation; Chronic myeloid leukemia; Relapse; Tyrosine kinase inhibitors

Indexed keywords

DASATINIB; HYDROXYUREA; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; ADVANCED CANCER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; BLOOD TOXICITY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPENIA; DONOR LYMPHOCYTE INFUSION; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LEUKEMIA RELAPSE; MALE; NEUTROPENIA; OVERALL SURVIVAL; PROGNOSIS; RETROSPECTIVE STUDY; THROMBOCYTOPENIA;

ADULT; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACCELERATED PHASE; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS;

EID: 77951209065     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.11.026     Document Type: Article

References (29)

1. Silver R.T., Woolf S.H., Hehlmann R., et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 1999, 94:1517-1536.
2. Goldman J.M., Rizzo J.D., Jabocinski K.A., et al. Long term outcome after allogeneic stem cell transplantation for CML (abstract). Hematol J 2004, 5:98. [Abstract no. 266].
3. Kolb H., Schmid C., Barrett A.J., Schendel D.J. Graft versus leukemia reactions in allogeneic chimeras. Blood 2004, 103:767-776.
4. Dazzi F., Szydlo R., Cross N.C.P., et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allografting for chronic myeloid leukemia. Blood 2000, 96:2712-2716.
5. Kolb H.J., Schattenberg A., Goldman J.M., et al. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995, 86:2041-2050.
6. Tomblyn M., Lazarus H.M. Donor lymphocyte infusions: the long and winding road: how should it be traveled?. Bone Marrow Transplant 2008, 42:569-579.
7. Druker B.J., Tamura S., Buchdunger E., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996, 2:561-566.
8. Druker B., Guilhot F., O'Brien S., et al. Five-year follow-up of imatinib therapy for newly diagnosed chronic myelogenous leukemia in chronic-phase shows sustained responses and high overall survival. N Engl J Med 2006, 355:2408-2417.
9. Kantarjian H.M., O'Brien S., Cortes J.E., et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2002, 100:1590-1595.
10. Olavarria E., Ottmann O.G., Deininger M., et al. Chronic Leukemia Working Party of the European Group of Bone and Marrow Transplantation (EBMT). Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 2003, 17:1707-1712.
11. DeAngelo D.J., Hochberg E.P., Alyea E.P., et al. Extended follow-up of patients treated with imatinib mesylate (Gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. Clin Cancer Res 2004, 10:5065-5071.
12. Hess G., Bunjes D., Siegert W., et al. Sustained complete molecular remissions after treatment with imatinib mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. J Clin Oncol 2005, 23:7583-7593.
13. Weisser M., Tischer J., Schnittiger S., et al. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. Haematologica 2006, 91:663-666.
14. Savani B.N., Montero A., Kurlander R., et al. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant 2005, 36:1009-1015.
15. Martinez C., Gomez V., Tomas J.F., et al. CML subcommittee of the Spanish Group of Hematopoietic Transplantation (Grupo Espanol de Trasplante Hemopoyetico, GETH). Relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: outcome and prognostic factors. The Chronic Myeloid Leukemia Subcommittee of the GETH (Grupo Espanol de Trasplante Hemopoyetico). Bone Marrow Transplant 2005, 36:301-306.
16. Hughes T., Branford S. Molecular monitoring of chronic myeloid leukemia. Semin Hematol 2003, 40:62-68.
17. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
18. Silver R.T., Talpaz M., Sawyers C.L., et al. Four years of follow-up of 1027 patients with late chronic phase, accelerated phase, or blast crisis chronic myeloid leukemia treated with imatinib in three large phase II trials [abstract]. Blood 2004, 104:11. a [Abstract no. 23].
19. Guglielmi C., Arcese W., Hermans J., et al. Chronic Leukemia Working Party of the European Group of Bone and Marrow Transplantation (EBMT). Risk assessment in patients with Ph+ chronic myelogenous leukemia at first relapse after allogeneic stem cell transplant: an EBMT retrospective analysis. Blood 2000, 95:3328-3334.
20. Colombat M., Fort M.P., Chollet C., et al. Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment. Haematologica 2006, 91:162-168.
21. Branford S., Lawrence R., Grigg A., et al. Long term follow up of patients in chronic phase treated with first-line imatinib suggests that earlier achievement of a major molecular response leads to greater stability of response (abstract). Blood 2008, 112:735-736. [Abstract 2113].
22. Branford S., Seymour J.F., Grigg A., et al. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res 2007, 13:7080-7085.
23. Hughes T.P., Kaeda J., Branford S., et al. International Randomized Study of Interferon versus STI571 (IRIS) Study Group. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003, 349:1423-1432.
24. Hughes T., Branford S. Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukemia. Blood Rev 2006, 20:29-41.
25. Olivarria E., Kanfer E., Szydlo R., et al. Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2001, 97:1560-1565.
26. Kaeda J., O'Shea D., Szydlo R., et al. Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplant for chronic myeloid leukemia: an attempt to define patients who may not require further therapy. Blood 2006, 107:4171-4176.
27. Mughal T.I., Yong A., Szydlo R.M., et al. Molecular studies in patients with chronic myeloid leukemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse. Br J Haematol 2001, 115:569-574.
28. Radich J.P., Gooley T., Bryant E., et al. The significance of BCR-ABL molecular detection in chronic myeloid leukemia patients ″ late,″ 18 months or more after transplant. Blood 2001, 98:1701-1707.
29. Baccarani M., Saglio G., Goldman J., et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood 2006, 108:1809-1820.